Latest Arul Chinnaiyan Stories

Study to evaluate whether drug works better against tumors with specific genetic anomaly ANN ARBOR, Mich., May 23, 2013 /PRNewswire-USNewswire/ -- Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients - the next question is to figure out how to match the right treatments with the right patients. A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to...

FREMONT, Calif., Jan. 28, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the results of a successful study of lncRNA markers associated with prostate cancer in the lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center. The results can be viewed in white paper form at: http://www.wafergen.com/wp-content/uploads/2013/01/UM_lncRNA_TNf.pdf Under an existing agreement, WaferGen holds a license to this and other lncRNA-based research...

CLEVELAND, Jan. 23, 2013 /PRNewswire/ -- A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of breast cancer. Published in Science Translational Medicine, the study lays the early foundation for predicting which breast cancer patients may develop...

Discovery illuminates a promising path for future research and treatment of breast cancer with personalized medicine Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers. These types of genetic recombinations have previously been linked to blood cancers and rare soft-tissue tumors, but are beginning to be discovered in common solid tumors, including a large...

About half of prostate cancers have a genetic anomaly that appears to make tumor cells responsive to a new class of cancer-fighting drugs, a new study from the University of Michigan Comprehensive Cancer Center finds.The drugs, called PARP inhibitors, are currently being tested in breast cancer patients with mutations in the BRCA1 and BRCA2 genes, which are found in up to 10 percent of all breast cancers.Half of prostate cancers have a genomic rearrangement that causes the fusion of two genes...

Known cancer-linked gene involved in subset of advanced tumorsResearchers at the University of Michigan Comprehensive Cancer Center have identified a genetic anomaly that may drive the aggressive spread of a rare subset of prostate cancers.They found mutations of a gene called KRAS, which is known to play a role in numerous cancers but is rarely associated with prostate cancer. The mutation "“ in which two pieces of the chromosome change places and fuse together "“ was seen only in...

Drugs should be developed to target gene fusions in prostate cancer, research showsProstate cancer treatments that target the hormone androgen and its receptor may be going after the wrong source, according to a new study. Researchers have found that when two genes fuse together to cause prostate cancer, it blocks the receptor for the hormone androgen, preventing prostate cells from developing normally. The study, from the University of Michigan Comprehensive Cancer Center, suggests that...

Researchers link hormone to creation of gene fusion in prostate cancer ANN ARBOR, Mich., Oct. 30 /PRNewswire-USNewswire/ -- Researchers at the University of Michigan Comprehensive Cancer Center have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop. The study found that pieces of chromosome relocate near each other after exposure to the hormone androgen. This sets the scene for the gene fusion to occur. The finding is...

Researchers link hormone to creation of gene fusion in prostate cancerResearchers at the University of Michigan Comprehensive Cancer Center have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop.The study found that pieces of chromosome relocate near each other after exposure to the hormone androgen. This sets the scene for the gene fusion to occur. The finding is reported online Oct. 29 in Science Express."This work...

 Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers. The results may lead to more accurate prostate cancer testing and new targets for potential treatments. Experts believe that gene fusions "” a hybrid gene formed from two previously separated genes "” may be at the root of what causes cancer cells to grow more quickly than normal cells.The new findings, published in the...